EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

YKT6 Promotes Bladder Cancer Progression by Stabilizing β‐catenin Through USP7‐Mediated Deubiquitination

Sheng Tu, Wenzhi Du, Yongwen Luo, Jiageng Shi, Tianyun Liu, Meng Ji, Kangping Xiong, Siming Chen, Fenfang Zhou, Mingxing Li, Jingtian Yu, Gang Wang und 5 weitere

Advanced Science · 2026-02 · 13 (8)

DOI: 10.1002/advs.202507166 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 26.11.2025. Verfasst von Sheng Tu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, beta Catenin, Ubiquitin-Specific Peptidase 7. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hubei Provincial Science and Technology Plan Project, Research Fund of Zhongnan Hospital of Wuhan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bladder cancer (BLCA) remains a highly lethal genitourinary malignancy with complex tumor biology and limited therapeutic strategies. This study investigates the oncogenic role of YKT6, a SNARE protein, in BLCA progression and molecular mechanisms. It is demonstrated that YKT6 is significantly upregulated in BLCA tissues and cell lines, correlating with advanced tumor grade, aggressive histology, and poor patient prognosis from public datasets and tissue microarray. Transcriptomic and functional analyses reveal that YKT6 promotes BLCA cell proliferation, migration, and metastasis both in vitro and in vivo. Mechanistically, YKT6 activates the Wnt/β‐catenin signaling pathway through a novel mechanism involving USP7‐mediated deubiquitination of β‐catenin. By recruiting USP7, YKT6 inhibits β‐catenin's proteasomal degradation, thereby stabilizing the protein and driving nuclear accumulation. This stabilization leads to increased expression of oncogenic target genes and induces epithelial‐mesenchymal transition (EMT). Pharmacological interventions demonstrate that Wnt signaling inhibition reverses YKT6‐driven malignant effects, while pathway activation restores tumor progression in YKT6‐silenced cells. USP7 knockdown abrogates YKT6‐mediated β‐catenin stabilization, confirming their functional interdependence. Clinically, the YKT6/USP7/β‐catenin axis strongly correlates with poor prognosis, providing a proof‐of‐concept for the druggability of this axis. The findings unveil YKT6 as a novel regulator of Wnt signaling through USP7‐dependent deubiquitination, offering insights for precision BLCA therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder Neoplasmsbeta CateninUbiquitin-Specific Peptidase 7HumansUbiquitinationMiceDisease ProgressionAnimalsCell Line, TumorWnt Signaling PathwayEpithelial-Mesenchymal TransitionCell ProliferationMaleGene Expression Regulation, NeoplasticFemaleMice, Nude

Stichwörter der Autor:innen

USP7Wnt/β‐catenin signalingYKT6bladder cancerubiquitination

Substanzen

beta CateninUbiquitin-Specific Peptidase 7USP7 protein, humanCTNNB1 protein, human

Autor:innen und Institutionen

  • Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
  • Hubei Key Laboratory of Urological Diseases, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
  • Department of Urology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, 250014, China.
  • Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
  • Department of Radiology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
  • Department of Biological Repositories, Human Genetic Resources Preservation Center of Hubei Province, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.

ORCID-Profile: Yu Xiao, Xinghuan Wang, Kaiyu Qian

Förderung

  • Hubei Provincial Science and Technology Plan Project
  • Research Fund of Zhongnan Hospital of Wuhan University

Zitieren

APA

Tu, S., Du, W., Luo, Y., Shi, J., Liu, T., Ji, M., Xiong, K., Chen, S., Zhou, F., Li, M., Yu, J., Wang, G., Ju, L., Zhang, Y., Xiao, Y., Wang, X., & Qian, K. (2026). YKT6 Promotes Bladder Cancer Progression by Stabilizing β‐catenin Through USP7‐Mediated Deubiquitination. Advanced Science, 13(8). https://doi.org/10.1002/advs.202507166

Vancouver

Tu S, Du W, Luo Y, Shi J, Liu T, Ji M, et al. YKT6 Promotes Bladder Cancer Progression by Stabilizing β‐catenin Through USP7‐Mediated Deubiquitination. Advanced Science. 2026;13(8). doi:10.1002/advs.202507166

BibTeX
@article{Tu2026,
  author = {Tu, Sheng and Du, Wenzhi and Luo, Yongwen and Shi, Jiageng and Liu, Tianyun and Ji, Meng and Xiong, Kangping and Chen, Siming and Zhou, Fenfang and Li, Mingxing and Yu, Jingtian and Wang, Gang and Ju, Lingao and Zhang, Yi and Xiao, Yu and Wang, Xinghuan and Qian, Kaiyu},
  title = {YKT6 Promotes Bladder Cancer Progression by Stabilizing β‐catenin Through USP7‐Mediated Deubiquitination},
  journal = {Advanced Science},
  year = {2026},
  volume = {13},
  number = {8},
  doi = {10.1002/advs.202507166}
}
Kostenlos starten →